Two years of treatment with the approved therapy >Copaxone (glatiramer acetate) was found to slow the loss of cerebral gray matter and whole brain volume — two markers of neurodegeneration — in people with relapsing-remitting multiple sclerosis (RRMS). Notably, individuals on Copaxone…
gray matter
People with relapsing multiple sclerosis who have disability progression, but no clinical relapses, show significantly faster brain shrinkage, or atrophy, than those with a stable disease, a study shows. There were no significant differences in the brain atrophy rate between patients with progression independent of relapse activity (PIRA) and…
Disease severity, brain volume loss, and brain lesions are able to predict later cognitive declines in people with relapsing-remitting multiple sclerosis (RRMS), a study in China found. The study, “Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: a 2-year longitudinal study,”…
Subtle changes in structure in the hippocampus — a region of the brain involved in processing memories — can differentiate between relapsing-remitting and primary progressive multiple sclerosis, according to a new study. The study, “Unraveling the MRI-Based Microstructural Signatures Behind Primary Progressive and Relapsing–Remitting Multiple Sclerosis Phenotypes,”…
People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest. Data from this same Phase 3…
Learning a second language can bolster the health-related quality of life and mental well-being of people with multiple sclerosis (MS) by working to expand areas of the brain involved in language and damaged by MS, especially in early disease stages, a study suggests. These findings were reported in the…
With the help of 7 Tesla magnetic resonance imaging (MRI), investigators discovered that leptomeningeal enhancement — a radiographic finding indicative of brain inflammation — is more common than previously thought in people with relapsing-remitting multiple sclerosis (RRMS), and is tied to lesions in specific regions of the brain.
Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topic “Grey Matter Atrophy in MS Shown to Follow a Pattern” from July…
Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal, The American Journal of Managed Care (AJMC). The free and online video series is part…
Treatment with Gilenya (fingolimod) may limit cerebral gray matter atrophy in relapsing-remitting multiple sclerosis (RRMS) patients, researchers at Boston’s Brigham and Women’s Hospital have found. Their report, “A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis,” appeared in the…
Loss of spinal cord neurons may not be a reliable tool to predict disability in patients with multiple sclerosis (MS), contrary to what was originally thought, according to researchers at Queen Mary University of London. Their study, “Axonal loss in the multiple sclerosis spinal cord revisited,” appeared in the journal…
The less oxygen that a mouse with multiple sclerosis (MS) has in the gray matter of its brain, the more mental and physical deterioration it is likely to have, a new study suggests. The study confirms previous research indicating a connection between low oxygen levels in a mouse’s gray matter and the development…
Immune activity in brain membranes may be the key to determining inflammatory profiles in the brain. These profiles, in turn, are linked to levels of brain gray matter damage, and to disability, in both early and later stages of multiple sclerosis (MS). Researchers behind the study, which was presented during the Parallel…
Researchers found that nerve cell connections in the brain, called synapses, were damaged in a mouse model of multiple sclerosis (MS) through a process wholly unrelated to myelin destruction. As the damaged mice synapses studied were in regions crucial for memory processing, finding ways of protecting these neurons would be a crucial step toward developing a…
In a recent study published in the journal PLOS One, a team of researchers explored the differences in cognitive performance and magnetic resonance imaging (MRI) correlates of cognitive deficits in patients with relapsing-remitting multiple sclerosis (RRMS) and patients with primary progressive multiple sclerosis (PPMS) to underscore the importance…
Loss of myelin, the fatty protective sheath around nerve fibers, is a characteristic of multiple sclerosis (MS). A new magnetic resonance imaging (MRI) study by a team of researchers has determined that people with MS lose myelin in the gray matter of their brains, and that the amount of loss…